Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
The discovery of BRAF mutations in the majority of patients with metastatic melanoma combined with the identification of highly selective BRAF inhibitors have revolutionized the treatment of patients with metastatic melanoma. The first highly specific BRAF inhibitor, vemurafenib, began clinical test...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064951/ |